G. Requena

First name
G.
Last name
Requena
Brauer, R., Ruigomez, A., Downey, G., Bate, A., Rodriguez, L. A. G., Huerta, C., et al. (2016). Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3831
View
Requena, G., Huerta, C., Gardarsdottir, H., Logie, J., Gonzalez-Gonzalez, R., Abbing-Karahagopian, V., et al. (2016). Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3816
View
Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., et al. (2016). Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3825
View
Requena, G., Wolf, A., Williams, R., Dedman, D., Quint, J. K., Murray-Thomas, T., & Pimenta, J. M. (2020). Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5188
View
Requena, G., Ma, L., Sturmer, T., Layton, J. B., & DiBello, J. (2020). Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events. Clin Drug Investig. http://doi.org/10.1007/s40261-020-00935-1
View
Requena, G., Dedman, D., Quint, J. K., Ghosh, R. E., Williams, R., & Pimenta, J. M. (2021). The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s291931
View
Requena, G., Logie, J., Gibbons, D. C., Steinfeld, J., & Van Dyke, M. K. (2021). The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom. Immun Inflamm Dis. http://doi.org/10.1002/iid3.495
View